- Home
- Publications
- Publication Search
- Publication Details
Title
Gemtuzumab ozogamicin in acute myeloid leukemia revisited
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 14, Issue 8, Pages 1185-1195
Publisher
Informa Healthcare
Online
2014-05-28
DOI
10.1517/14712598.2014.922534
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
- (2013) S. Nand et al. BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Antibody therapy for acute myeloid leukaemia
- (2013) Robin E. Gasiorowski et al. BRITISH JOURNAL OF HAEMATOLOGY
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
- (2013) Hagop Kantarjian et al. CANCER
- Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
- (2013) R. B. Walter et al. HAEMATOLOGICA
- Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice
- (2013) Martin S. Tallman et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)
- (2013) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia
- (2013) R. F. Schlenk et al. Hematology-American Society of Hematology Education Program
- Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse
- (2012) J. V. Malfuson et al. ANNALS OF HEMATOLOGY
- Reprise: Gemtuzumab Ozogamicin for Older Patients With Acute Myeloid Leukemia
- (2012) Donna S. Neuberg JOURNAL OF CLINICAL ONCOLOGY
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
- (2012) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
- (2012) A K Burnett et al. LEUKEMIA
- Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin
- (2012) M Kurimoto et al. LEUKEMIA
- Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association
- (2011) Hassan Farhat et al. AMERICAN JOURNAL OF HEMATOLOGY
- Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients
- (2011) U. Brunnberg et al. ANNALS OF ONCOLOGY
- The Incidence of Veno-Occlusive Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Has Diminished and the Outcome Improved over the Last Decade
- (2011) Enric Carreras et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?
- (2011) Maciej Bogdan Maniecki et al. LEUKEMIA RESEARCH
- Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
- (2010) B. Lowenberg et al. BLOOD
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
- (2010) Richard M. Stone et al. LEUKEMIA RESEARCH
- Gemtuzumab Ozogamicin Therapy for Isolated Extramedullary AML Relapse after Allogeneic Hematopoietic Stem-Cell Transplantation
- (2010) Toshihiko Ando et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin
- (2009) P Chevallier et al. LEUKEMIA
- Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+Primary Resistant or Relapsed Acute Myeloid Leukemia
- (2008) Patrice Chevallier et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
- (2008) Richard F. Schlenk et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now